Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC. (PubMed, Clin Cancer Res) - Oct 9, 2026 - "Our findings indicate that secondary RET mutations can impart drug-specific effects on resistance to SRIs. These results underscore the need for precision therapy based on the specific resistance mutations present."
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • RET
|
|
Abeeb Yekeen; Alvaro G Paula; Ashwani Kumar; Haniel A Araujo; John V Heymach; Junqin He; Kaiwen Wang; Kenneth D Westover; Li Cai; Monique B Nilsson; Ralf Kittler; Xiaofang Huo; Ximeng Liu
|